1. Shah VP, Skelly JP. Regulatory considerations in transdermal drug delivery systems in the United States. In: Chien YW, Editor. Transdermal controlled systemic medication. New York: Marcel Dekker; 1987. pp. 399–410.
2. Peck CC, Shah VP. FDA requirements for approval of transdermal drug delivery systems. Scott RC, Guy RH, Hadgraft J, Editors. Proceedings of “Prediction of Percutaneous Penetration-Methods, Measurements. Modeling.” Oxford: IBC Technical Services; 1989. pp. 286–9.
3. Marshall K, Foster TS, Carlin HS, Williams RL. Development of a compendial taxonomy and glossary for pharmaceutical dosage forms. Pharmacop Forum. 2003;29(5):1742–52.
4. Williams RL, Thakker KM, John V, Lin ET, Liang-Gee W, Benet LZ. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. Pharm Res. 1991;8:744–9.
5. FDA/CDER Guideline for Format and content of the human pharmacokinetics and bioavailability section of an application. February 1987.